← Human Trials & Peer-Reviewed Studies
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial
Plain-language guide to PMID 38078870 (2024): double-blind randomized controlled trial study of Tirzepatide and GIP (Gastric Inhibitory Polypeptide) in 670 participants.
Key Facts
- PMID
- 38078870
- Journal
- JAMA
- Year
- 2024
- Study type
- Randomized Controlled Trial
- Authors
- Aronne LJ et al. (12 authors)
- DOI
- 10.1001/jama.2023.24945
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Tirzepatide and GIP (Gastric Inhibitory Polypeptide), published as a randomized controlled trial.
Who Took Part
The abstract describes 670 participants taking part.
The age groups tagged for this paper are adults and middle-aged adults, both men and women.
This phase 3, randomized withdrawal clinical trial conducted at 70 sites in 4 countries with a 36-week, open-label tirzepatide lead-in period followed by a 52-week, double-blind, placebo-controlled period included adults with a body mass index greater than or equal to 30 or greater than or equal to 27 and a weight-related complication, excluding diabetes.
At week 36, a total of 670 participants were randomized (1:1) to continue receiving tirzepatide (n = 335) or switch to placebo (n = 335) for 52 weeks.
How the Study Was Run
The design is described as randomized, double-blind, open-label and placebo-controlled.
Random assignment meant chance, not the researchers, decided who got Tirzepatide and who got the comparison, which limits bias.
Blinding on both sides kept the participants and researchers unaware of who received Tirzepatide.
Being open-label, the Tirzepatide study did not mask who received what.
Some participants received a placebo instead of Tirzepatide, giving a reference point.
The methods mention a period of 52 weeks.
What Was Measured
PubMed files the paper under topics including Gastric Inhibitory Polypeptide, Obesity, Overweight, Weight Loss, Glucagon-Like Peptide-2 Receptor, Incretins and Anti-Obesity Agents.
What This Means in Plain Language
The paper is a randomized, double-blind and open-label study of Tirzepatide and GIP (Gastric Inhibitory Polypeptide) in 670 participants over 52 weeks.
With several hundred people or more, it is a fairly large study for this kind of research.
The abstract goes on to report its results in about 8 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2024 (JAMA), a journal based in United States.
More context: the Tirzepatide compound page and the GIP (Gastric Inhibitory Polypeptide) compound page, all human trials.
Our Notes on the Compounds
Tirzepatide: A prescription peptide medicine that acts on both the GIP and GLP-1 receptors; Mounjaro and Zepbound contain the same active ingredient.
GIP (Gastric Inhibitory Polypeptide): A 42-amino-acid gut hormone that boosts insulin release after meals; one of the two receptors tirzepatide acts on.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.